Search

Search Results

• EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

  Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan

  e2026033

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.033

  207

  PDF: 211

  Suppl. Files: 36

  HTML: 14

• THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis

  Kun Yang, Jian Xiao

  e2024001

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.001

  1387

  PDF: 1420

  PDF: 1008

  HTML: 213

• THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

  Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin

  e2020021

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.021

  2183

  PDF: 1230

  HTML: 335

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2544

  PDF: 714

  HTML: 1530

• Thalidomide treatment for thrombocytopenia secondary to hypersplenism in children with β-thalassemia major: a case series Thalidomide treatment for thrombocytopenia

  Kun Yang

  e2025037

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.037

  879

  PDF: 735

  HTML: 114

• Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

  Alhossain A. Khalafallah, Matthias Maiwald, Amanda Cox, Burns Denise, Gerald Bates, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain

  e2010005

  2010-04-20

  https://doi.org/10.4084/mjhid.2010.005

  1147

  PDF: 574

  HTML: 1142

• THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

  Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

  e2010009

  2010-05-03

  https://doi.org/10.4084/mjhid.2010.009

  1075

  PDF: 714

  HTML: 619

• EFFECTS OF THALIDOMIDE ON ENDOTHELIAL ACTIVATION AND STRESS INDEX IN CHILDREN WITH Β-THALASSEMIA MAJOR

  Kun Yang

  e2024076

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.076

  1060

  PDF: 573

  HTML: 149

• POEMS SYNDROME: AN UPDATE

  Andrea Nozza

  e2017051

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.051

  3302

  PDF: 1638

  HTML: 1504

• LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

  Patrizia Tosi

  e2013037

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.037

  1279

  PDF: 894

  HTML: 1276

  fig 1A: 172

  figure1B: 147

• REAL WORLD MULTIPLE MYELOMA REGISTRY FROM JORDAN, A DEVELOPING COUNTRY.

  Abdalla Awidi, Farah Qasem, A'sem Abu-Qamar, Batool Aqel, Rand Aladayleh, Ilham Alteerah, Ahmad Magableh, , Hisham Bawa”neh, Feras Al-fararjeh

  e2022031

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.031

  1276

  PDF: 724

  HTML: 363

• "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

  Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

  e2010013

  2010-06-01

  https://doi.org/10.4084/mjhid.2010.013

  1413

  PDF: 662

  HTML: 1507

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  1928

  PDF: 1640

  HTML: 124

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5266

  PDF: 1921

  HTML: 1360

• EARLY APPLICATION OF HIGH CUT-OFF HAEMODYALISIS FOR DE-NOVO MYELOMA NEPHROPATHY IS ASSOCIATED WITH LONG-TERM DIALYSIS-INDEPENDENCY AND RENAL RECOVERY

  Alhossain A. Khalafallah, Sie Wuong Loi, Sarah Love, Muhajir B. Mohamed, Rose Mace, Ramy Khalil, Miriam Girgs, Rajesh Raj, Mathew Mathew

  e2013007

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.007

  1355

  PDF: 659

  HTML: 2500

  cover letter: 194

• COMPREHENSIVE REVIEW OF GENETIC AND EPIGENETICS REGULATION OF FETAL HEMOGLOBIN IN β-HEMOGLOBINOPATHIES: FROM MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS HbF Genetics in Anemia

  Yousef Saeed Mohammad Abu Za’ror, Joseph Bagi Suleiman, Fatima Azzahra Delmani, Jehad Farouq Alhmoud, Amer Mohammad Ayasreh, Sarah Ihsan Al-wendawi, Maryam Azlan

  e2026046

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.046

  408

  PDF: 298

  HTML: 20

• FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

  Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni

  e2024066

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.066

  1056

  PDF: 622

  Html: 155

• THE DARK SIDE OF THE COVID-19 TREATMENTS ON MYCOBACTERIUM TUBERCULOSIS INFECTION

  Flavio De Maio, Delia Mercedes Bianco, Giovanni Delogu

  e2022021

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.021

  1280

  PDF: 748

  HTML: 229

• Common variable immunodeficiency due to a novel NFKB1 variant in a child with thalassemia major CVID with thalassemia major

  Kun Yang

  e2023053

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.053

  705

  PDF: 558

  HTML: 163

• VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS

  Anna M. Randi, Mike A Laffan, Richard D. Starke

  e2013060

  2013-09-02

  https://doi.org/10.4084/mjhid.2013.060

  3748

  PDF: 1564

  HTML: 8032

  Randi Fig: 182

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2455

  PDF: 786

  HTML: 1736

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1518

  PDF: 805

  HTML: 155

• Impact of daratumumab on stem cell mobilization and transplant in patient with newly diagnosed multiple myeloma: a real word single-center study

  Mauro Passucci, Francesca Fazio, Jacopo Micozzi, Manhaz Shafii Bafti, Giovanni Manfredi Assanto, Alfonso Piciocchi, Maurizio Martelli, Maria Teresa Petrucci

  e2024041

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.041

  1261

  PDF: 1046

  Suppl. Files: 709

  HTML: 73

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  5540

  PDF: 2316

  HTML: 1329

• IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

  Jean Elcheikh

  e2013026

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.026

  1293

  PDF: 738

  HTML: 1414

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7526

  PDF: 2422

  HTML: 1734

  Table 1.: 208

  Table 2.: 217

  Table 3.: 202

  Table 4.: 200

• Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy

  Gianluca Cavallaro

  e2024049

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.049

  2216

  HTML: 141

  PDF: 1117

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1350

  PDF: 831

  HTML: 135

• Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience

  Edoardo Olivari

  e2025040

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.040

  1043

  PDF: 770

  HTML: 151

• RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

  Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2023062

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.062

  1196

  PDF: 1072

  HTML: 203

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1669

  PDF: 647

  HTML: 2433

• Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

  Jacopo Monticelli, Roberto Luzzati, Cristina Maurel, Chiara Rosin, Romina Valentinotti, Claudio Farina

  e2015011

  2014-12-24

  https://doi.org/10.4084/mjhid.2015.011

  1694

  PDF: 1090

  HTML: 6520

  original file with images: 279

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1583

  PDF: 605

  HTML: 191

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4326

  PDF: 1765

  HTML: 1107

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1757

  PDF: 1670

  HTML: 862

• Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

  Alessandro Gozzetti, Vania Rossi, Alfonso Cerase, Giulia Papini, Marzia Defina, Monica Bocchia

  e2012041

  2012-06-19

  https://doi.org/10.4084/mjhid.2012.041

  1105

  PDF: 661

  HTML: 669

• Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

  Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà, Maria Teresa Petrucci

  e2012035

  2012-05-07

  https://doi.org/10.4084/mjhid.2012.035

  1547

  PDF: 744

  HTML: 646

• A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

  Mauro Passucci, Francesca Fazio, Maria Teresa Petrucci

  e2023012

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.012

  891

  PDF: 945

  HTML: 414

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1518

  PDF: 1343

  HTML: 114

• ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication

  Maria Chiara Tisi, Giuseppe Ausoni, Maria Gabriella Vita, Tommaso Tartaglione, Mario Balducci, Luca Laurenti, Patrizia Chiusolo, Stefan Hohaus, Simona Sica

  e2015025

  2015-02-17

  https://doi.org/10.4084/mjhid.2015.025

  2380

  PDF: 998

  HTML: 1648

  Fig 1: 185

  Tab I: 213

  Cover Letter: 205

• REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Giovanni D'arena, Giovanni Rossi, Barbara Vannata, Silvia Deaglio

  e2012053

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.053

  2330

  PDF: 989

  HTML: 7624

  Untitled: 277

  Fig2: 184

  Fig3: 169

  Fig4: 181

• QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

  Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods

  e2011057

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.057

  1394

  PDF: 681

  HTML: 1378

  cover letter: 206

• Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma

  Vincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, Chiara Carrara, Monica Bocchia, Alessandro Gozzetti

  e2025051

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.051

  738

  PDF: 574

  HTML: 31

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1424

  PDF: 1224

  HTML: 268

• PROGNOSTIC IMPACT OF NEUROPILIN-1 EXPRESSION IN EGYPTIAN CHILDREN WITH B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA

  adel abd elhaleim hagag, Nahla A Nosair

  e2015009

  2014-12-28

  https://doi.org/10.4084/mjhid.2015.009

  1641

  PDF: 819

  HTML: 2111

• Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia

  xiaolin yin, Jingting Luo

  e2023050

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.050

  753

  PDF: 545

  HTML: 161

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1173

  PDF: 959

  HTML: 148

• EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

  Pietro Tralongo, Arianna Bakacs, Luigi Maria Larocca

  e2024042

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.042

  4107

  PDF: 1653

  HTML: 961

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2806

  PDF: 1010

  HTML: 5521

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  2038

  PDF: 827

  HTML: 247